TABLE 2.

Serum HAI antibody titers and GMFRs in response to the A/H1N1, A/H3N2, and B virus strains in seronegative subjectsa

Strain and treatmentncGeometric meanb HAI titer (95% CI)GMFR (95% CI)
PrevaccinationPostvaccination
A/H1N1
    CAIV-T 107332.04 (1.96, 2.13)3.92 (2.68, 5.73)1.92 (1.31, 2.81)
    CAIV-T <105292.00 (2.00, 2.00)2.31 (1.72, 3.10)1.15 (0.86, 1.55)
    TIV302.00 (2.00, 2.00)2.89 (2.27, 3.69)1.45 (1.14, 1.84)
    Placebo302.00 (2.00, 2.00)2.52 (1.85, 3.42)1.26 (0.93, 1.71)
A/H3N2
    CAIV-T 107332.13 (1.98, 2.29)23.35 (13.91, 39.20)10.96 (6.63, 18.13)
    CAIV-T <105342.13 (1.98, 2.28)2.72 (1.98, 3.73)1.28 (0.92, 1.77)
    TIV352.04 (1.96, 2.12)3.35 (2.58, 4.34)1.64 (1.27, 2.12)
    Placebo342.17 (2.00, 2.35)2.72 (2.01, 3.66)1.25 (0.92, 1.70)
B
    CAIV-T 107272.27 (2.04, 2.53)15.59 (9.18, 26.48)6.86 (3.98, 11.83)
    CAIV-T <105212.14 (1.94, 2.35)3.74 (2.19, 6.40)1.75 (1.01, 3.04)
    TIV262.23 (3.01, 2.47)3.60 (2.23, 5.81)1.62 (1.06, 2.45)
    Placebo242.31 (2.05, 2.61)4.62 (2.77, 7.70)2.00 (1.18, 3.38)
  • a A subject was seronegative to a particular strain if his or her prevaccination HAI titer to that strain was ≤1:4.

  • b Geometric mean, antilog of the mean of the log-transformed titer or fold rise.

  • c n, number of subjects in the calculation.